GLP-1 & Weight Loss

Retatrutide, tirzepatide, semaglutide, orforglipron and other GLP-1 weight loss drugs.

NA-931 Cuts Weight Without Major Muscle Loss in Mid-Stage Trial

NA-931 Cuts Weight Without Major Muscle Loss in Mid-Stage Trial

An experimental oral medicine called NA-931 led to substantial weight loss with only modest reductions in lean mass in a randomized phase II trial. Researchers from developer Biomed Industries presented the topline results at the ObesityWeek annual meeting. The highest doses reduced body weight by 13.8% and 11.3% at week 13, compared with 1.9% on placebo. Lean mass fell by 1.7% over the same period, and nausea rates were only slightly higher than placebo. The company says it is advancing NA-931 into phase III testing. The findings are early and come from a small study of 125 adults.

FDA Adds Vision Loss Warning to GLP-1 Drugs, Leaving Doctors and Patients With Hard Choices

FDA Adds Vision Loss Warning to GLP-1 Drugs, Leaving Doctors and Patients With Hard Choices

The FDA will require new warnings across the entire GLP-1 drug class about a possible increased risk of NAION, a rare condition that damages the optic nerve and can cause permanent vision loss. The class includes Ozempic, Wegovy, Zepbound and Mounjaro. Because the drugs are widely used, the warning forces a difficult question: when a patient develops NAION, should treatment stop? Regulators in Europe and the U.S. have answered differently. An ophthalmologist who has asked patients about GLP-1 use for two years says the FDA should now study what happens after a diagnosis, and that patients cannot wait years for answers.

Two Case Reports Link Abrupt Tirzepatide Discontinuation to Mania and Psychosis

Two Case Reports Link Abrupt Tirzepatide Discontinuation to Mania and Psychosis

Two men were hospitalized with acute psychiatric symptoms after abruptly stopping tirzepatide, the active ingredient in Mounjaro and Zepbound, according to case studies published in The Primary Care Companion for Central Nervous System Disorders. One patient showed signs of psychosis, including hallucinations and a rare delusion that he was dead, while the other was diagnosed with a manic episode. The authors do not claim the drug withdrawal caused the symptoms. They say the timing is worth attention and that prescribers should consider recent changes in GLP-1 medication when evaluating patients with new mood or psychotic symptoms.

GLP-1 Side Effects Draw Scrutiny as Measles and Ebola Cases Climb

GLP-1 Side Effects Draw Scrutiny as Measles and Ebola Cases Climb

The Washington Post is examining the rare but serious side effects linked to GLP-1 receptor agonists, including ischemic optic neuropathy, gallstones and pancreatitis. The health news roundup also covers a new HIPAA rule requiring providers to answer health data requests within 15 days, an NIH leadership appointment, and an FDA nominee the White House is reportedly weighing dropping. Measles cases continue to rise in the U.S., and Ebola is hitting children hard in the Congo, according to UNICEF.

Wegovy Cuts BMI in Children With Obesity as Young as 6, Trial Finds

Wegovy Cuts BMI in Children With Obesity as Young as 6, Trial Finds

Wegovy (semaglutide) significantly reduced body mass index in children ages 6 to 11 with obesity, according to results from the phase III STEP Young trial. Presented at the ObesityWeek annual meeting and published in the New England Journal of Medicine, the study found that treated children lost weight while placebo patients gained it. Researchers also reported slower height gain and frequent gastrointestinal side effects. Drugmaker Novo Nordisk has not said whether it will submit the data to the FDA.

Cheaper GLP-1 Generics Arrive, and a Global Access Fight May Follow

Cheaper GLP-1 Generics Arrive, and a Global Access Fight May Follow

Lower-cost generic versions of semaglutide, the drug sold as Wegovy by Novo Nordisk for obesity, have begun reaching some countries and will soon arrive in others. At the same time, drugmakers are racing to develop newer GLP-1 medicines that are forecast to be more effective, cause fewer side effects and be easier to administer. London School of Economics professor Ken Shadlen, who studies the politics of pharmaceutical and health regulation, warns that obesity medications could become the next major battleground over access to medicines in lower-income countries. The shifts could put weight-loss treatment within reach of more people, but the path to access is far from settled.

Tirzepatide Cuts BMI Sharply in Adolescents With Obesity, Phase III Trial Finds

Tirzepatide Cuts BMI Sharply in Adolescents With Obesity, Phase III Trial Finds

Tirzepatide (Zepbound) produced substantial reductions in body mass index among adolescents with obesity in the phase III SURMOUNT-ADOLESCENTS trial. At week 72, participants on the once-weekly GLP-1/GIP drug alongside a healthy lifestyle program saw an 18.5% mean BMI reduction, while those on placebo saw a 0.5% increase. The trial met its primary endpoint, and all 10 key secondary outcomes also favored tirzepatide. Results were presented at the ObesityWeek annual meeting and published in JAMA. The researchers cautioned against escalating doses to the maximum tolerated level in routine care.

Hundreds of English Children Prescribed Weight-Loss Jabs, Figures Show

Hundreds of English Children Prescribed Weight-Loss Jabs, Figures Show

Hundreds of children in England are receiving prescriptions for GLP-1 medications, including some under 12, according to a Guardian investigation of NHS prescribing data. In the 2025-26 financial year, 419 prescriptions were issued to under-18s, 10 of them to children under 12. Experts say the figures likely understate the true total, and they stress that children who start these drugs need specialist supervision and long-term monitoring. The findings come as childhood obesity rates continue to rise and as new global guidance advises against giving obesity medications to children under 10.

Why Community Pharmacies May Be the Key to Staying on GLP-1 Medications

Why Community Pharmacies May Be the Key to Staying on GLP-1 Medications

A new Milken Institute report, released alongside survey research, argues that community pharmacies can play a central role in helping patients stay on GLP-1 medications. Real-world data cited in the report indicates that roughly 47% to 68% of people stop treatment within the first year, and nearly three in four GLP-1 users say more time with a pharmacist would improve their experience and results. The report points to side effects during dose changes, prior authorization hurdles, and out-of-pocket costs as common reasons patients abandon therapy. It also highlights pharmacy-led check-ins, navigation support, and clearer reimbursement pathways as practical steps that could help patients and pharmacy teams stay on track over the long term.

GLP-1 Drugs Linked to Better Survival After Liver Transplant

GLP-1 Drugs Linked to Better Survival After Liver Transplant

Liver transplant patients who took GLP-1 receptor agonists after surgery were 45% less likely to die than those who did not, according to a retrospective three-center study of 2,402 patients presented at the American Association for the Study of Liver Diseases Liver Meeting in Denver. A replication cohort of 1,443 U.S. claims-database patients showed similar results. Researchers said the drugs appear to lower deaths from causes other than liver failure, including cardiovascular events and cancer, though the reasons remain unclear and the study has limits. The findings add to a growing case for metabolic care in transplant patients as fatty liver disease becomes a leading cause of transplant.

Former Eli Lilly Rep Says She Was Fired After Objecting to Mounjaro Marketing

Former Eli Lilly Rep Says She Was Fired After Objecting to Mounjaro Marketing

A former Eli Lilly sales representative has filed a federal lawsuit in Texas alleging she was fired after complaining that the company promoted its Mounjaro diabetes drug for weight loss before the Food and Drug Administration had approved that use. Jennifer Mansion, who was hired as a senior territory manager in Dallas four years ago, says she saw other Lilly reps pitch the drug as a treatment for obesity. She also alleges a physician touted Mounjaro as a weight loss option at a luncheon sponsored by the drugmaker. The case raises questions about off-label marketing, which federal rules prohibit drugmakers from doing for unapproved uses.

FDA Requires New Vision Loss Warning on All GLP-1 Drugs

FDA Requires New Vision Loss Warning on All GLP-1 Drugs

The U.S. Food and Drug Administration is requiring manufacturers of all GLP-1 receptor agonist medications to add a warning about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause painless vision loss in one eye and can be permanent. The agency's review included a meta-analysis of 126 clinical trials and a retrospective cohort study. Its findings showed a higher incidence of NAION among patients taking GLP-1 drugs than among those receiving comparator treatments, though the absolute numbers remain small. Health care providers are advised to watch for sudden vision changes and to refer suspected cases to an ophthalmologist.

Retatrutide Eases Knee Osteoarthritis Pain in Patients With Obesity, Trial Finds

Retatrutide Eases Knee Osteoarthritis Pain in Patients With Obesity, Trial Finds

An investigational obesity drug, retatrutide, significantly reduced pain and improved physical function in adults with obesity and knee osteoarthritis, according to the phase 3 TRIUMPH-4 trial. Results were presented at the American College of Rheumatology annual meeting and published simultaneously in the New England Journal of Medicine. The drug targets three hormone receptors and produced substantial weight loss, but a higher rate of side effects than placebo, and the researchers called for further studies on how it works and whether it can modify the disease itself.

Retatrutide Is One Click Away, but That Does Not Make It Safe

Retatrutide Is One Click Away, but That Does Not Make It Safe

Retatrutide, an investigational weight-loss and diabetes drug, is being sold online as a “research” product even though it has no FDA approval for any use. Federal regulators say federal law does not permit it to be compounded or sold, and clinicians warn that gray-market vials may contain the wrong dose, impurities, or no retatrutide at all. Promising trial data on the approved-for-study molecule do not establish that online products are safe or effective.

GLP-1 Medications Compared With Metformin for Prediabetes: What the Study Found

GLP-1 Medications Compared With Metformin for Prediabetes: What the Study Found

A study presented at the American Heart Association Scientific Sessions 2026 found that adults with prediabetes and obesity who took a GLP-1 medication were about 1.5 times more likely than those on metformin to regulate their blood sugar. They also had a 31% lower risk of progressing to type 2 diabetes. The observational analysis reviewed electronic health records from 256,492 adults and reported fewer heart attacks, strokes, and heart failure events among GLP-1 users. Researchers say the results could shape conversations between doctors and patients about treatment options, though metformin remains a first-line choice.

Weight-Loss Incretin Drug Linked to More Regular Periods

Weight-Loss Incretin Drug Linked to More Regular Periods

A combined GLP-1/GIP receptor agonist was associated with more regular menstrual cycles in a prospective cohort study presented at the American Society for Reproductive Medicine annual meeting. Women taking the combination drug saw their cycle length shorten by an average of 2.5 days, compared with 0.4 days for GLP-1 users and 0.8 days for never-users. The effect was most pronounced among women with polyendocrine metabolic ovarian syndrome, formerly known as polycystic ovary syndrome. Researchers at the Harvard T.H. Chan School of Public Health led the analysis of data from more than 70,000 logged cycles. The team says the findings could help drugmakers explore new ways to support ovulation.

A Court Ruling on GLP-1 Ads, a Weekly Insulin for Kids, and Other Health Stories to Know

A Court Ruling on GLP-1 Ads, a Weekly Insulin for Kids, and Other Health Stories to Know

A U.S. judge rejected Novo Nordisk's request to temporarily block Eli Lilly from running ads claiming its weight-loss and diabetes drugs are more powerful. The same week, the FDA expanded approval for a once-weekly insulin for children ages 10 and older with type 2 diabetes. Studies also showed endocrinologists prescribing newer diabetes drugs more often and GLP-1 use among Medicare beneficiaries rising sharply. Here is a friendly rundown of what changed, what it means, and what to keep in mind.

Semaglutide and Fewer Asthma Attacks: What the New Data Shows

Semaglutide and Fewer Asthma Attacks: What the New Data Shows

A large real-world study presented at the ERS Congress in Barcelona found that people with asthma who started semaglutide, sold as Ozempic and Wegovy, had nearly 40% fewer asthma attacks than similar patients on a different diabetes medication. Researchers also reported lower COPD flare-ups and a possible link to fewer psychiatric hospitalizations. The findings are observational, and the researchers say they should not change how GLP-1 drugs are prescribed until clinical trials confirm them.

Nearly 1 in 6 Pediatric GLP-1 Patients Diagnosed With Nutritional Deficiency Within a Year

Nearly 1 in 6 Pediatric GLP-1 Patients Diagnosed With Nutritional Deficiency Within a Year

Nearly one in six children and adolescents who started a GLP-1 receptor agonist were diagnosed with a nutritional deficiency or deficiency-related complication within one year, according to a retrospective analysis of insurance claims published in Childhood Obesity. Vitamin D deficiency was the most common diagnosis. The study also found that nutrition counseling was infrequent and often began months after treatment started. The authors cautioned that the findings do not show counseling causes deficiencies and that a study designed to test causation is needed. The analysis covered 2,031 patients aged 10 to 17 years, drawn from claims data from 2017 to 2022.

CagriSema Shows Weight Loss Across Menopause Stages, Including Women on Hormone Therapy

CagriSema Shows Weight Loss Across Menopause Stages, Including Women on Hormone Therapy

New data from a post-hoc analysis of Novo Nordisk's REDEFINE 1 trial suggest that the investigational combination CagriSema produced clinically meaningful weight loss in women at every menopause stage studied, including those using hormone therapy. Presented at The Menopause Society's 2026 Annual Meeting, the analysis of 1,902 women found mean reductions of 23.1% to 26.7% over 68 weeks, along with improvements in blood pressure, fasting glucose, and triglycerides. The findings are investigational and come from a post-hoc analysis, so they do not establish how the drug will perform in practice. An FDA decision is anticipated in late 2026, and pharmacists are expected to play a key role in counseling patients.

Peptide ETFs Multiply as Wall Street Chases the Wellness Trend

Peptide ETFs Multiply as Wall Street Chases the Wellness Trend

REX Shares recently launched the REX Peptide ETF (PEPT), a fund holding companies that develop and manufacture peptide products, including GLP-1 drugs. Eli Lilly and Novo Nordisk are among its holdings. AdvisorShares has filed for a competing fund, the Peptide and Human Enhancement ETF. Other firms are also building wellness-themed funds, but investor money has not yet kept pace with the buzz. Some funds have seen outflows, and analysts say the sector's appeal may depend on timing and the broader market.

Retatrutide Eases Sleep Apnea in Two Phase III Trials

Retatrutide Eases Sleep Apnea in Two Phase III Trials

Retatrutide, an experimental triple agonist that targets GIP, GLP-1 and glucagon receptors, improved obstructive sleep apnea in adults with obesity or overweight, according to two parallel randomized trials. The results were presented at the Congress of the European Sleep Research Society and published in the New England Journal of Medicine. Researchers found effects similar to those seen with tirzepatide, the first drug approved to treat sleep apnea, though the trials did not directly compare the two medications.

Low T in Army Men, GLP-1 Blood Pressure Data and Retatrutide Side Effects Make the News

Low T in Army Men, GLP-1 Blood Pressure Data and Retatrutide Side Effects Make the News

A new round of health research points to a wide range of hormone and metabolic findings. Roughly a quarter of active-duty U.S. Army men had a morning testosterone level under 300 ng/dL, a common cutoff for low testosterone. A CDC report found nearly half of American women ages 40 to 60 reported menopausal symptoms in 2025, and 15.6% of them took prescription medication for those symptoms. Separate studies linked GLP-1 drugs to blood pressure drops and early anti-aging signals. Novo Nordisk reported weight-loss results in women, and Walmart said it will cover over 250 prescription drugs, including some GLP-1 drugs for diabetes, for employees in 2027. An analysis of Reddit posts also cataloged side effects reported by users of the unapproved weight-loss drug retatrutide.

GLP-1 Drugs Do Not Change Injection Needs for Diabetic Macular Edema, Study Finds

GLP-1 Drugs Do Not Change Injection Needs for Diabetic Macular Edema, Study Finds

GLP-1 receptor agonists did not significantly change how often patients with diabetic macular edema needed anti-VEGF injections, according to a large retrospective cohort study presented at the American Academy of Ophthalmology meeting in New Orleans. Over 24 months of follow-up, treatment frequency showed no sustained or progressive change after patients started a GLP-1 drug, compared with matched patients who did not. Visual acuity and retinal thickness also held steady. Researchers said the results are reassuring amid ongoing uncertainty about the drugs' eye safety, though they cautioned that more research is needed.